Background. Multiple viruses coinfect the male genital tract, influencing each other's replication and perhaps affecting human immunodeficiency virus (HIV) pathogenesis and disease progression.
Several studies have shown that HIV coinfection provides a synergistic effect for the replication of HHV, especially in the genital tract, where HHV shedding commonly fluctuates [24, 25] . Both cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are reactivated as a result of changes to the cytokine network caused by HIV coinfection [26] and as a consequence of HIV-induced immune dysfunction [18] . In general, HIV-infected individuals have higher rates of HHV shedding compared with HIVuninfected individuals [25] , with varying effects depending upon the particular HHV type and cohort characteristics [27] [28] [29] .
We previously described the rates of genital HHV replication and their association with genital levels of HIV RNA in a cross-sectional cohort of treated HIV-infected persons [30] and longitudinally during untreated HIV infection [31] . However, no study has described the longitudinal dynamics of genital HHV shedding during treated and untreated early HIV infection and what factors might impact the shedding of these viruses.
part of the San Diego Primary Infection Resource Consortium (PIRC) between 1997 and 2014. The estimated dates of infection was established using a series of well-defined stepwise rules that characterize stages of infection based on serologic and virologic criteria, as described in [32] (and summarized in Supplementary Table 1) . Routine study visits included regular lymphocyte counts and plasma viral loads. Semen was collected and processed as previously described [16, 33] .
We also collected a single seminal sample from a similar cohort of 67 "at risk" HIV-uninfected control participants.
The studies were conducted with appropriate written subject consent and were approved by the Human Research Protections Program at the University of California, San Diego.
Quantification of HIV RNA and HHV DNA in Seminal Plasma
HIV RNA levels were measured in seminal plasma by first concentrating HIV RNA from 500 μL of seminal plasma with high-speed centrifugation (23 500g at 4°C for 1 hour) after 1:1 dilution with phosphate-buffered saline [16] . Concentrated RNA was extracted using the High Pure Viral RNA Kit (Roche) and HIV complementary cDNA was generated using the SuperScript III First-Strand Synthesis Kit (Invitrogen) with specific primer mf302 [34] . HIV RNA in seminal plasma was quantified by real-time polymerase chain reaction (PCR) in an ABI 7900HT thermocycler (Applied Biosystems) [16, 35] . HIV RNA quantification standards were obtained from the Division of AIDS (DAIDS) Virology Quality Assurance (VQA) program [36] . Similarly, levels of 7 herpesviruses (CMV, EBV, herpes simplex virus types 1/2 [HSV-1/2], and human herpesvirus types 6, 7, and 8 [HHV-6, HHV-7, HHV-8]) were measured in DNA extracted from seminal plasma by real-time PCR [37] . Varicella zoster virus was not included as it is typically not detected in seminal plasma.
Statistical Analysis
Statistical analysis was performed using SAS software (version 9.4). Viral loads were transformed to logarithmic scales. Continuous variables were compared and expressed as median with interquartile range (IQR). Seminal HIV and HHV shedding were dichotomized based upon presence of any detectable virus. Proportions were compared using Fisher exact test or χ 2 test as appropriate. Shedding rates of individual virus types were determined over the course of 1 year (ie, 365 days) by survival analysis using Kaplan-Meier estimates. Comparisons between groups were done by log-rank test. Factors associated with genital viral shedding were analyzed in generalized estimating equation (GEE) models using a subset of participants with the following characteristics: available visits that had a viral load within 7 days, visits that were at least 7 days apart, and no more than 6 visits per subject. The GEE approximated relative risk through a modified Poisson model with an autoregressive correlation matrix that adjusted for multiple visits [38] . Because of the exploratory/descriptive character of this analysis, results were not adjusted for multiple comparisons. Participants with ≥2 visits (with HHV detectable in at least 1 seminal sample) separated by >30 days were further classified based upon shedding pattern of each HHV. Specifically, shedding was classified as "persistent" if all longitudinal time points remained positive. Otherwise, shedding was classified as "intermittent. "
RESULTS

HIV-Infected Study Participants and Baseline Samples
A total of 453 seminal samples from 195 HIV-infected men were analyzed. All participants were men who have sex with men (MSM) diagnosed with acute and early HIV infection, prospectively enrolled in the PIRC, and willing to provide semen samples ( Table 1 
HIV-Uninfected Healthy Controls
A total of 67 HIV-uninfected healthy controls were enrolled as part of this study. Median age was 36 (IQR 35-41) years, 87% were MSM, and 21% were on tenofovir/emtricitabine for preexposure prophylaxis within the previous month of the sample collection. HHV shedding of any type in semen was present in 25 participants (37.3%), specifically: 1 (1.5%) HSV-1/2; 13 (19.4%) CMV; 9 (13.4%) EBV; 1 (1.5%) HHV-6; 6 (9.0%) HHV-7; and 1 (1.5%) HHV-8. Compared with HIV-infected individuals measured on their first visit, the HIV-uninfected controls were significantly less likely to present any HHV shedding (37.3% vs 62.6%; P < .001), CMV shedding (19.4% vs 47.2%; P < .0001), or EBV shedding (13.4% vs 28.7%; P < .01).
Frequency of HHV-8 shedding was also lower (1.5% vs 6.7%; P = .13) but did not reach statistical significance. There was no significant difference for shedding of HSV-1 or -2 (1.5% vs 3.6%; P > .2), HHV-6 (1.5% vs 3.1%; P > .2), or HHV-7 (9% vs 9.2%; P > .2).
Longitudinal Patterns of Seminal Herpesviruses and HIV Shedding
Half of HIV-infected participants (97 of 195) had 1 or more longitudinal visits with a median of 3 (IQR, 2-4) seminal samples provided over a median follow-up of 111 (IQR, 36-230) days.
There was no significant difference by race/ethnicity or age between participants who had follow-up visits and those who did not (all P > .05). Using Kaplan-Meier methods in the full cohort of HIV-infected men (treated and untreated), we determined the time to HHV shedding and the overall cumulative shedding rates (ie, the percentage with any shedding) of HHV in semen over an observed period of 365 days from baseline. Based on this analysis, 94.3% of early HIV-infected individuals presented detectable DNA for at least 1 HHV in at least 1 sampled time point over a period of 365 days. This included 86% with CMV DNA shedding, 71% with EBV DNA shedding, 23% with HSV shedding (type 1 or 2), 30% with HHV-6 shedding, 36% with HHV-7 shedding, and 27% with HHV-8 shedding ( Figure 1 ). To determine if factors such as age, ART status, HIV RNA levels, and CD4 + T-cell counts affected HHV shedding, we generated GEE models (Table 2) . When considering all HHVs as a group, there were no statistically significant factors associated with presence of seminal shedding. However, subanalysis of each HHV revealed some distinctions. Older age was associated with a decreased shedding rate for EBV and HHV-7 (with 27% and 73% reduction, respectively, in shedding rates per decade of age). Interestingly, longer time from estimated HIV infection was significantly associated with a decrease in the shedding rate of HSV (types 1 and 2) and an increase in the shedding rates of HHV-6 and EBV (all P < .05). directly associated with presence or absence of HHV-7. HSV-1/2, EBV, and HHV-8 also presented reduced shedding rates in the presence of ART use, but these were not statistically significant. ART usage had no effect on CMV and HHV-6 shedding.
Overall, CMV and HHV-8 shedding were not modified by any factors we measured. For those HHV with >1 significant modifying factor, we performed multivariate analysis and all factors remained significantly associated with viral shedding in the multivariable models.
In participants with at least 1 follow-up visit, we investigated the shedding pattern for each HHV virus ("intermittent" vs "persistent"). As an example, of the 16 men who ever shed HSV-1/2 and with at least 2 time points, 8 men shed virus intermittently (50%) while 8 men presented HSV-1/2 at all their time points (ie, persistent shedding pattern). Similar shedding pattern rates were observed for HHV-6 (54%), HHV-7 (43%), and HHV-8 (50%). In comparison, persistent shedding was found more frequently for CMV and EBV, which had intermittent shedding proportions of 19% and 34%, respectively ( Figure 2 ).
Associations Between HHV and HIV RNA Semen Shedding
Last, we used univariate and multivariable GEE modeling to determine associations between seminal shedding of HIV RNA and seminal shedding of the various types of HHV (Table 3) . In univariate analysis, higher HIV RNA levels, no ART use, shorter time since infection, lower CD4 + T-cell count, higher CD8 + T-cell count, and presence of CMV, EBV, HHV-6, and HSV shedding were all significantly associated with presence of seminal HIV RNA shedding (all P < .05). In multivariate analysis, only plasma HIV RNA levels and shedding of CMV, EBV, and HSV remained independently associated with seminal HIV RNA shedding. In particular, for every log 10 viral load increase in the blood plasma, there was an increase in seminal plasma shedding (adjusted RR, Unfortunately, the sample size was too small to perform a separate model for suppressed people, but it is interesting to note that a third of time points with suppressed HIV RNA in plasma during ART had simultaneous detectable HIV RNA in semen during the first year of infection.
DISCUSSION
As part of this study, we used the longitudinal data of 195 HIVinfected men with 453 longitudinal seminal samples followed from primary infection to examine factors associated with viral shedding over a period of 48 weeks of follow-up. As previously reported, shedding of HHV was more common in HIVinfected individuals compared with uninfected healthy controls, despite early HIV infection and high CD4 + T-cell counts [39] . Specifically, we observed that CMV and EBV are highly prevalent during the first 48 weeks of HIV infection, followed by HHV-7, HHV-8, HSV, and HHV-6 [8, 40] . Interestingly, the shedding rates of most HHVs did not seem to be affected by ART status, HIV RNA levels, or CD4 + T-cell counts. A notable exception was HHV-7, which was significantly reduced by ART, but this effect did not correlate with HIV RNA level of CD4 + count, suggesting a possible direct drug effect on the virus. For HSV-1/2 and HHV-8, the small sample size may have impaired our ability to detect a more modest effect of ART on shedding. Younger age was a positive factor in shedding for EBV and HHV-7, and early HIV infection was associated with higher shedding rates in HSV-1/2 and HHV-6. We also determined the shedding patterns of these HHVs ("persistent shedding" vs "intermittent shedding") on a subset of participants with ≥2 longitudinal seminal samples. As shown in Figure 2 , HSV, HHV-6, HHV-7, and HHV-8 were somewhat evenly distributed between intermittent and persistent shedding patterns. On the contrary, notably more participants were identified as persistent shedders for both CMV (81%) and EBV (66%). Various factors could result in such differences, including differences in HHV pathogenesis, replication dynamics, collection methods of genital secretion, and other technical issues [14, 25] . This observation might have important clinical consequences as coinfections with HHV (and CMV in particular) have been associated with immunosenescence, inflammation, and aging, particularly during HIV infection but also with various non-AIDS-related complications [22, 23, 41] . Furthermore, HIV-infected individuals can present very high levels of CMV-specific T cells (up to 50% of CD4 + T cells and even higher for CD8 + T cells), which might be a consequence of persistent exposure to CMV antigens, and are associated with cardiovascular complications [16, 17, 23, 42] . We have also shown that shedding of HHV may be associated with comorbidities such as acquisition of syphilis and persistence of human papillomavirus infections [43, 44] . Understanding the pattern and frequency of subclinical viral replication is important to inform future studies of anti-HHV therapy (in particular CMV) and to determine which patient population might particularly benefit from such interventions.
Several studies described associations between various HHVs and genital HIV shedding, with potential implications for HIV transmission. As expected, our study found an association between HIV RNA in blood and seminal plasma [11, 35] . We further confirmed associations between HIV RNA shedding and CMV, EBV, and HSV-1/2. Notably, HSV was less frequent and mostly intermittent (compared with CMV and EBV) but when it was present, its association with HIV shedding was very strong. This is consistent with several studies showing that HSV-2 increases the risk of both HIV acquisition and transmission [9] . Interestingly, one-third of early HIV-infected participants on ART and with suppressed HIV RNA in blood plasma presented detectable HIV RNA in semen. This is higher than what we found in a cohort of chronically HIV-infected people on long-term ART [45] and consistent with the fact that HIV RNA in semen might take longer to suppress than in blood.
This study has several limitations. Because this is an observational cohort study with varied numbers of visits and time between visits, we relied on estimates of shedding rates over time using Kaplan-Meier methods (ie, there was censoring of many who did not reach 1 year of follow-up). Also, not all assessments were completed at the same visit; for example, viral loads and ART use were not always assessed at sampling time points and certain data had to be excluded from the analyses. Also, HHV serologies were not available for this cohort (except for EBV and CMV) and shedding rates are therefore reported at a population level rather than stratified by serological status. It is also not clear if HHV replication in the male genital tract is a surrogate for lower-level replication systemically or just a consequence of localized genital viral shedding. As part of this study, we did not measure levels of HHV DNA in blood or any other compartment, but this should be pursued in future studies. Similarly, the clinical significance of genital viral shedding is unclear. For example, the presence of HHV-8 shedding might predict an increased risk for Kaposi sarcoma if participants remained untreated for their HIV, but this is purely speculative and a connection between subclinical HHV-8 genital shedding and Kaposi sarcoma is currently unknown. Finally, we only measured levels of HIV and 7 HHVs as part of this study, but various other viruses are replicating in semen at high levels (eg, Zika) and might interact directly or indirectly through alteration in the microenvironment and should be investigated as part of future clinical trials.
Finally, we only had a very limited number of participants who started ART and continued to provide samples throughout the study, which limited our power to perform a subanalysis of the intraperson change in HHV before and after ART initiation. In summary, we collected seminal samples from a large group of early HIV-infected people on and off ART, and we characterized the longitudinal detection of HHV shedding. We found differences of shedding patterns by HHV type and variation in factors that might affect shedding. Most HHV shedding does not appear to be significantly modified by ART use, CD4 + count, or HIV RNA load, although HHV-7 does seem to be largely curtailed by ART and there is some trend for both HSV-1/2 and HHV-8 to also be reduced. Considering the abundance of HHV in HIV-infected men, there remains a need for further understanding of the pathogenesis of HHV in HIV and whether treatment of HHV might be beneficial in managing HIV.
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